Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Official Title

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

Keywords

Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin Lymphoma, Zimberelimab

Eligibility

Locations

  • UCLA Department of Medicine - Hematology/Oncology
    Los Angeles California 90095 United States
  • START South Texas Accelerated Research Therapeutics - Mountain Region
    West Valley City Utah 84119 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Arcus Biosciences, Inc.
Links
ARC-12 - Public website
ID
NCT04772989
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 94 people participating
Last Updated